Welcome to our dedicated page for IMMUTEP SEC filings (Ticker: PRRUF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IMMUTEP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IMMUTEP's regulatory disclosures and financial reporting.
IMMUTEP Ltd Chief Development Officer Christian Mueller filed an initial ownership report showing he directly holds 3,774,048 Ordinary Shares. This Form 3 establishes his baseline equity position as a company officer.
Mueller also holds three tranches of performance rights over 1,400,000 Ordinary Shares in total, each with a zero exercise price. Footnotes state 466,667 performance rights are scheduled to vest on December 1, 2026 and another 466,667 on December 1, 2027, while 466,666 are scheduled to vest on December 1, 2028. Vesting of the latter two tranches depends on him achieving specified key performance indicators at each applicable vesting date.
Immutep Limited reported that the Independent Data Monitoring Committee for its TACTI-004 Phase III trial in first-line non-small cell lung cancer has recommended discontinuing the study after a planned interim futility analysis. Enrolment will stop and the company will wind down the trial with patient follow up and site close out.
The study tested eftilagimod alfa in combination with pembrolizumab and chemotherapy versus pembrolizumab, chemotherapy and placebo, targeting about 756 patients across more than 150 sites in over 25 countries. Following the discontinuation, Immutep now anticipates its cash runway will extend well beyond its prior Q2 CY2027 guidance and plans to reassess capital allocation once data review is complete.
Immutep Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish an exhibit describing a new research collaboration. The exhibit, titled “Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti,” indicates that the company and the George Washington University Cancer Center plan to evaluate neoadjuvant Efti in a cancer setting. This Form 6-K serves as the formal vehicle to provide that collaboration announcement to investors and regulators.